Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adobe

DexCom

Microsoft

NVIDIA

ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.

ESG Stocks Remain Resilient to Virus Slump: 5 Top Picks

Eli Lilly (NYSE: LLY) shares are trading higher on Monday amid overall strength in the health care sector.

Why Eli Lilly's Stock Is Trading Higher Today

BioMarin Pharmaceutical

Incyte

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

We are only in May, but 2020 is already one of the most incredible years in stock market history.

5 Top Health Care Stocks to Buy Now on the Goldman Sachs Conviction List

Retevmo, the asset that inspired Eli Lilly's acquisition of Loxo Oncology, has earned approval to treat aggressive tumors.

Eli Lilly's $8 Billion Oncology Bet Gets Its Chance to Succeed

Gilead Sciences

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.

Government to test remdesivir with Lilly drug in COVID-19 patients

Amgen

Bristol-Myers

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.

5 Biopharmas Where BofA Would Put Its Money To Work

GlaxoSmithKline

Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.
The post 3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline

The company expects its financial results to get a boost as a result of the ongoing outbreak.

After Its Strong First-Quarter Results, Should You Buy Shares of Eli Lilly?

Abbott Labs

Johnson & Johnson

Healthcare stocks are pulling the market higher today. Here are three of the best stocks to buy in the sector right now.

3 Healthcare Stocks Popping Off Support

The pharmaceutical companies have not been immune to the current coronavirus crisis, although they have fared much better than the broader markets. While Bristol-Myers Squibb has declined -3.5% since early February, after the WHO declared the coronavirus a global health emergency.

Should You Sell Eli Lilly To Buy Bristol-Myers Squibb?

Domino's Pizza

Walmart

While many stocks have suffered during the coronavirus crisis, some have thrived. Here are three winners that are the best stocks to buy.

3 Bullish Coronavirus Stocks to Trade Into Weakness

Bull of the Day: Eli Lilly (LLY)

It's going to take more than the COVID-19 pandemic to stop this big pharma freight train.

4 Reasons Eli Lilly Stock Can Keep on Climbing

Chipotle

Intel

Netflix

Snap

The coronavirus stock market rally retreated this week as crude oil prices went negative, but the overall action was constructive.
The post Coronavirus Stock Market Rally Pauses As Crude Oil Prices Go Negative; Netflix, Snap, Intel, Domino's, Chipotle, Eli Lilly Report appeared first on Investor's Business Daily.

Coronavirus Stock Market Rally Pauses As Crude Oil Prices Go Negative; Netflix, Snap, Intel, Domino's, Chipotle, Eli Lilly Report

As of late, it has definitely been a great time to be an investor Eli Lilly and Company

Will Eli Lilly and Company Continue to Surge Higher?

Inovio Pharmaceuticals

Las Vegas Sands

Eli Lilly, Domino's Pizza, Gilead Sciences, Las Vegas Sands and Inovio Pharmaceuticals were our top stock trades for Friday.

5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY

Pharmaceutical giant Eli Lilly crushed first-quarter expectations Thursday as the coronavirus pandemic stoked increased prescription drug buying. In response, LLY stock jumped.

Why The Coronavirus Pandemic Isn't Shaking This Red-Hot Pharma Stock

The company posted higher revenue as a result of the COVID-19 pandemic.

Eli Lilly Reports First-Quarter Results, Adjusts Guidance

Eli Lilly and Company (LLY) CEO Dave Ricks on Q1 2020 Results - Earnings Call Transcript

Eli Lilly (LLY) earnings for the American pharmaceutical company's first quarter of the year have LLY stock up on Thursday.
The post Eli Lilly Earnings: LLY Stock Leaps 2% on Q1 Beat appeared first on InvestorPlace.

Eli Lilly Earnings: LLY Stock Leaps 2% on Q1 Beat

Eli Lilly and Co (NYSE: LLY) released its quarterly earnings report on Thursday that topped analysts’ estimates for earnings and revenue. The company attributed the success to higher sales as customers stockpiled essential medicines like Trulicity (diabetes drug) to prepare for the Coronavirus driven lockdowns.

Eli Lilly’s quarterly revenue jumps 15% as customers stockpile drugs ahead of COVID-19 restrictions

The big drugmaker isn't as certain about how the novel coronavirus pandemic will impact it in the future.

How COVID-19 Actually Helped Boost Eli Lilly's Q1 Results

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know

Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.

Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits

Eli Lilly and Co  raised the top-end of its 2020 profit forecast on Thursday and beat quarterly estimates, benefiting from customers stocking up medicines such as diabetes drug Trulicity amid the coronavirus pandemic.

News for Eli Lilly Stock (LLY)